Hypoxia-inducible factor 1-alpha (HIF-1α) (HIF-1α)

Hypoxia-responsive drug targeting is a specialized therapeutic strategy designed to exploit the oxygen-depleted microenvironment characteristic of solid tumors and ischemic tissues. The primary molecular target of this strategy is the Hypoxia-inducible factor (HIF) signaling pathway, specifically the transcription factor Hypoxia-inducible factor 1-alpha (HIF-1α), which serves as the master regulator of the cellular adaptive response to low oxygen (UniProt: Q16665). Under hypoxia, HIF-1α stabilizes and translocates to the nucleus to induce the expression of over 100 genes involved in angiogenesis, metabolic reprogramming (Warburg effect), and cell survival, all of which contribute to tumor progression and therapeutic resistance (PubMed: 32662059). Pharmacological interventions include the development of small-molecule inhibitors such as belzutifan (targeting HIF-2α) and experimental HIF-1α inhibitors like PX-478, which disrupt these survival pathways. Additionally, the strategy encompasses hypoxia-activated prodrugs (HAPs) like evofosfamide, which are bioreductively triggered only in low-oxygen conditions to release potent cytotoxins, thereby sparing healthy normoxic tissues. Despite its potential, clinical success remains challenging due to tumor heterogeneity and the critical need for precise patient selection using biomarkers such as Carbonic anhydrase IX (CAIX) (NIH: ClinicalTrials.gov).

Other names

Hypoxia-inducible factor 1 subunit alphaHIF1AMember of PAS protein 1MOP1Basic-helix-loop-helix-PAS protein HIF-1-alpha

Drugs within this therapeutic strategy either directly inhibit the stabilization and transcriptional activity of the HIF-1α protein (e.g., HIF inhibitors) or utilize the hypoxic microenvironment to enzymatically convert non-toxic hypoxia-activated prodrugs (HAPs) into cytotoxic agents through bioreduction by endogenous enzymes such as Cytochrome P450 reductase.